MD4317B1 - Use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate for treating patients with advanced liver cirrhosis associated with heart failure - Google Patents

Use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate for treating patients with advanced liver cirrhosis associated with heart failure

Info

Publication number
MD4317B1
MD4317B1 MDA20130064A MD20130064A MD4317B1 MD 4317 B1 MD4317 B1 MD 4317B1 MD A20130064 A MDA20130064 A MD A20130064A MD 20130064 A MD20130064 A MD 20130064A MD 4317 B1 MD4317 B1 MD 4317B1
Authority
MD
Moldova
Prior art keywords
trimethylhydrazinium
heart failure
liver cirrhosis
treating patients
advanced liver
Prior art date
Application number
MDA20130064A
Other languages
Moldavian (mo)
Romanian (ro)
Russian (ru)
Other versions
MD4317C1 (en
Inventor
Gheorghe Anghelici
Oleg Crudu
Ulviyya Mammadova
Galina Pavliuc
Original Assignee
Gheorghe Anghelici
Oleg Crudu
Ulviyya Mammadova
Galina Pavliuc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gheorghe Anghelici, Oleg Crudu, Ulviyya Mammadova, Galina Pavliuc filed Critical Gheorghe Anghelici
Priority to MDA20130064A priority Critical patent/MD4317C1/en
Publication of MD4317B1 publication Critical patent/MD4317B1/en
Publication of MD4317C1 publication Critical patent/MD4317C1/en

Links

Abstract

The invention relates to medicine, particularly to hepatology.According to the invention, the use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate is claimed for treating advanced liver cirrhosis associated with heart failure, intravenously, 500 mg, 1…2 times a day, for 7…10 days, then per os, 500 mg, 1…2 times a day, for 4…6 weeks.
MDA20130064A 2013-09-12 2013-09-12 Use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate for treating patients with advanced liver cirrhosis associated with heart failure MD4317C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MDA20130064A MD4317C1 (en) 2013-09-12 2013-09-12 Use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate for treating patients with advanced liver cirrhosis associated with heart failure

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MDA20130064A MD4317C1 (en) 2013-09-12 2013-09-12 Use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate for treating patients with advanced liver cirrhosis associated with heart failure

Publications (2)

Publication Number Publication Date
MD4317B1 true MD4317B1 (en) 2015-01-31
MD4317C1 MD4317C1 (en) 2015-08-31

Family

ID=52440946

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20130064A MD4317C1 (en) 2013-09-12 2013-09-12 Use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate for treating patients with advanced liver cirrhosis associated with heart failure

Country Status (1)

Country Link
MD (1) MD4317C1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD4458C1 (en) * 2014-06-19 2017-08-31 Мария ДАНУ Use of Polybiolin drug in patients with liver cirrhosis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD4458C1 (en) * 2014-06-19 2017-08-31 Мария ДАНУ Use of Polybiolin drug in patients with liver cirrhosis

Also Published As

Publication number Publication date
MD4317C1 (en) 2015-08-31

Similar Documents

Publication Publication Date Title
BR112017010188A2 (en) phospholipid ether analogues as cancer-targeting drug carriers
CY1122469T1 (en) SUBLINGUAL PHARMACEUTICAL FORM OF RILOUZOLE
PH12016502352A1 (en) Pharmaceutical composition
EA201791110A1 (en) SUBLINGUAL INTRODUCTION OF RHYNESOL
EA201790726A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ULCERAL COLITIS
TW201613578A (en) Pharmaceutical combinations
BR112016029012A2 (en) method of treating non-small cell lung cancer and / or small cell lung cancer using thienotriazolodiazepine compounds
MX2016000294A (en) Pharmaceutical composition for a sustained release of lanreotide.
MX357763B (en) Treatment for pancreatic cancer.
SG11201804307WA (en) Therapeutic agent for liver disease containing stromal cells derived from adipose tissue and method for producing the same
BR112017002449A2 (en) treatment of symptoms associated with androgen deprivation therapy
MD4317C1 (en) Use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate for treating patients with advanced liver cirrhosis associated with heart failure
PH12016501026A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
MD4316C1 (en) Use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate for treating portal gastropathies in patients with liver cirrhosis
WO2014153505A3 (en) Treatment of chemotherapy-induced peripheral neuropathy
TW201613600A (en) Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically
MD4458C1 (en) Use of Polybiolin drug in patients with liver cirrhosis
UA83408U (en) Method for treatment of patients with chronic pancreatitis at comorbide cource of ischemic disease and syndrome of congestive heart failure
UA83410U (en) Method for treatment of patients with chronic pancreatitis with ischemic heart disease at congestive heart failure
UA91605U (en) Method for correcting disordered microcirculation in gastric mucosa of aged patients
PH12014000105A1 (en) Therapeutic methods and compositions for treating diabetes utilizing diterpenoid compounds
IN2014DE00822A (en)
RU2015122823A (en) METHOD FOR TREATMENT OF HEPATIC ENCEPHALOPATHY IN PATIENTS WITH HEPATIC CIRROSIS
IN2014DE00818A (en)
UA96488U (en) A method for treating disorders of hemovascular hemostasis in patients with ischemic heart disease

Legal Events

Date Code Title Description
FG4A Patent for invention issued
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees